Gemin X Biotechnologies Inc.

20 articles about Gemin X Biotechnologies Inc.

• Gemin X Biotechnologies Inc. to Present at the 29th Annual Cowen Healthcare Conference

  3/11/2009

• Senior Pharmaceutical Executive, Glenn J. Gormley, M.D., Ph.D., to Lead Gemin X Biotechnologies Inc. as President and CEO

  6/10/2008

• Tripos Discovery Research Ltd., a Subsidiary of Commonwealth Biotechnologies, Inc., Secures a Discovery Milestone Payment from Gemin X Biotechnologies Inc.

  8/7/2007

• Gemin X Biotechnologies Inc. Announces Publication in Blood of Positive Preclinical Data of Lead Compound in Mantle Cell Lymphoma

  5/15/2007

• Gemin X Biotechnologies Inc. Initiates a Phase 1 Trial with GMX1777 in Solid Tumors and Lymphomas

  5/8/2007

• Gemin X Biotechnologies Inc. Presents Positive Preclinical Data of GX15-070 in Infant ALL at American Association for Cancer Research Meeting

  4/18/2007

• Gemin X Biotechnologies Inc. Announces Publication of Preclinical Data of GX15-070 in Multiple Myeloma in Blood

  3/7/2007

• Gemin X Biotechnologies Inc. Initiates Phase 1/2 Combination Trials With GX15-070 In Non-Small Cell Lung Cancer And Mantle Cell Lymphoma

  1/31/2007

• Gemin X Biotechnologies Inc. To Present At The 25th Annual JPMorgan Healthcare Conference

  12/21/2006

• Gemin X Biotechnologies Inc.'s Pan-Bcl-2 Antagonist GX15-070 Permits Rational Combination With Velcade In Mantle Cell Lymphoma

  12/13/2006

• Data From Preclinical Studies of Gemin X Biotechnologies Inc.’s GX15-070 Presented In Five Posters At American Society of Hematology Annual Meeting

  12/12/2006

• Gemin X Biotechnologies Inc. Phase 1 Data Show Clinical Activity Of GX15-070 In Myelodysplastic Syndromes

  12/11/2006

• Review Of Clinical Data From Gemin X Biotechnologies Inc.'s GX15-070 Program Presented At The 24th Annual Chemotherapy Foundation Symposium

  11/9/2006

• Gemin X Biotechnologies Inc. Initiates Phase 2 Clinical Trial Program For GX15-070 In Myelofibrosis And Hodgkin's Lymphoma

  9/14/2006

• Gemin X Biotechnologies Inc. Pan-Bcl-2 Inhibitor, GX15-070, Shows Biological Activity In Refractory Solid Tumors And Lymphomas

  6/5/2006

• Preclinical Data Demonstrate Gemin X Biotechnologies Inc. Compound GX15-070 Induces Apoptosis In Mantle Cell Lymphoma And Exhibits Synergy With Velcade

  4/5/2006

• Tripos Discovery Research Centre Announces Partnerships With Industry-Leading Pharmaceutical And Life Science Companies

  1/25/2006

• Preclinical Studies Of Gemin X Biotechnologies Inc.'s GX15-070 Presented In Four Posters At American Society Of Hematology Annual Meeting

  12/13/2005

• Phase 1 Clinical Data Demonstrates Gemin X Biotechnologies Inc. Compound GX15-070 Is Well-Tolerated And Generates Biological And Clinical Improvements In CLL

  12/12/2005

• Gemin X Biotechnologies Appoints Andrew R. Jordan To Its Board Of Directors

  12/10/2003